Advanced Search
EurekAlert! Science News A service of the American Association for the Advancement of Science
EurekAlert! Science News A service of the American Association for the Advancement of Science
  • Home
  • News Releases
  • Multimedia
  • Meetings
  • Login
  • Register

RedHill Biopharma (IMAGE)

RedHill Biopharma

RedHill Biopharma

Caption

RedHill Biopharma

Credit

RedHill Biopharma Ltd

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Media Contact

Rob Cohen
RedHill Biopharma
rob@redhillbio.com
Office: 54-888-6095



More on this News Release

Redhill’s oral broad-acting antivirals, Opaganib and RHB-107, inhibit dominant Omicron sub-variant BA.5

RedHill Biopharma

Keywords

  • /Health and medicine/Diseases and disorders/Infectious diseases/Microbial infections/Viral infections/COVID 19
  • /Life sciences/Biochemistry/Pharmacology/Drug development/Drug candidates
  • /Life sciences/Genetics/Population genetics/Genetic variation
  • /Health and medicine/Epidemiology/Pathogens/Viruses/Coronavirus/SARS CoV 2
  • /Life sciences/Microbiology/Virology/Viral entry
  • /Research methods/Laboratory procedures/Cell cultures

Original Source

https://www.redhillbio.com/news/news-details/2022/RedHills-Oral-Broad-Acting-Antivirals-Opaganib-and-RHB-107-Inhibit-Dominant-Omicron-Sub-Variant-BA.5/default.aspx

EurekAlert! The Global Source for Science News

AAAS - American Association for the Advancement of Science

Copyright © 2025 by the American Association for the Advancement of Science (AAAS)

  • facebook.com/EurekAlert
  • @EurekAlert
  • youtube.com/EurekAlert

  • Help / FAQ
  • Services
  • Eligibility Guidelines
  • Contact EurekAlert!
  • Terms & Conditions
  • DMCA
  • Privacy Policy
  • Disclaimer

Copyright © 2025 by the American Association for the Advancement of Science (AAAS)